Laboratory for Molecular Endocrinology-GPCRs, Western Australian Institute for Medical Research (WAIMR) and Centre for Medical Research, The University of Western Australia, Nedlands, Western Australia, Australia.
PLoS One. 2013 May 20;8(5):e64672. doi: 10.1371/journal.pone.0064672. Print 2013.
Heteromerization can play an important role in regulating the activation and/or signal transduction of most forms of receptors, including receptor tyrosine kinases (RTKs). The study of receptor heteromerization has evolved extensively with the emergence of resonance energy transfer based approaches such as bioluminescence resonance energy transfer (BRET). Here, we report an adaptation of our Receptor-Heteromer Investigation Technology (Receptor-HIT) that has recently been published as the G protein-coupled receptor (GPCR) Heteromer Identification Technology (GPCR-HIT). We now demonstrate the utility of this approach for investigating RTK heteromerization by examining the functional interaction between the epidermal growth factor (EGF) receptor (EGFR; also known as erbB1/HER1) and heregulin (HRG) receptor 3 (HER3; also known as erbB3) in live HEK293FT cells using recruitment of growth factor receptor-bound protein 2 (Grb2) to the activated receptors. We found that EGFR and HER3 heteromerize specifically as demonstrated by HRG inducing a BRET signal between EGFR/Rluc8 and Grb2/Venus only when HER3 was co-expressed. Similarly, EGF stimulation promoted a specific BRET signal between HER3/Rluc8 and Grb2/Venus only when EGFR was co-expressed. Both EGF and HRG effects on Grb2 interaction are dose-dependent, and specifically blocked by EGFR inhibitor AG-1478. Furthermore, truncation of HER3 to remove the putative Grb2 binding sites appears to abolish EGF-induced Grb2 recruitment to the EGFR-HER3 heteromer. Our results support the concept that EGFR interacts with Grb2 in both constitutive and EGF-dependent manners and this interaction is independent of HER3 co-expression. In contrast, HER3-Grb2 interaction requires the heteromerization between EGFR and HER3. These findings clearly indicate the importance of EGFR-HER3 heteromerization in HER3-mediated Grb2-dependent signaling pathways and supports the central role of HER3 in the diversity and regulation of HER family functioning.
异源二聚化在调节大多数形式的受体(包括受体酪氨酸激酶(RTKs))的激活和/或信号转导中起着重要作用。随着基于共振能量转移的方法(如生物发光共振能量转移(BRET))的出现,受体异源二聚体的研究已经得到了广泛的发展。在这里,我们报告了我们最近发表的受体异源二聚体研究技术(Receptor-HIT)的一种改编,该技术被称为 G 蛋白偶联受体(GPCR)异源二聚体鉴定技术(GPCR-HIT)。我们现在通过检查表皮生长因子(EGF)受体(EGFR;也称为 erbB1/HER1)和人表皮生长因子受体 3(HER3;也称为 erbB3)之间的功能相互作用,证明了这种方法在研究 RTK 异源二聚体中的效用在活的 HEK293FT 细胞中使用生长因子受体结合蛋白 2(Grb2)募集到激活的受体。我们发现 EGFR 和 HER3 特异性异源二聚化,这是由 HRG 在仅当 HER3 共表达时诱导 EGFR/Rluc8 和 Grb2/Venus 之间的 BRET 信号证明的。同样,当共表达 EGFR 时,EGF 刺激促进了 HER3/Rluc8 和 Grb2/Venus 之间的特异性 BRET 信号。EGF 和 HRG 对 Grb2 相互作用的影响均呈剂量依赖性,并被 EGFR 抑制剂 AG-1478 特异性阻断。此外,截断 HER3 以去除假定的 Grb2 结合位点似乎会消除 EGF 诱导的 Grb2 募集到 EGFR-HER3 异源二聚体。我们的结果支持这样的概念,即 EGFR 以组成型和 EGF 依赖性方式与 Grb2 相互作用,并且这种相互作用与 HER3 共表达无关。相比之下,HER3-Grb2 相互作用需要 EGFR 和 HER3 之间的异源二聚化。这些发现清楚地表明 EGFR-HER3 异源二聚化在 HER3 介导的 Grb2 依赖性信号通路中的重要性,并支持 HER3 在 HER 家族功能的多样性和调节中的核心作用。